Recipharm Pharmaceutical Development and Synthonics, Inc. have entered a joint promotion agreement to provide Recipharm customers full access to Synthonics’ metal coordination chemistry to improve the delivery and performance of compounds.
 
Recipharm PD’s general manager, Maria Lundberg, said, “We are pleased to partner with Synthonics to expand the services and solutions that we can offer our clients. The application of Synthonics’ chemistry improves important characteristics such as bioavailability and solubility and thus increases the likelihood that promising molecules will become viable products. Furthermore, our ability to offer such services through this novel partnership distinguishes us from other CDMOs.”
 
Ken Slepicka, chief executive officer of Synthonics, said, “Synthonics is delighted to partner with Recipharm to help advance promising molecules to market. We are very impressed with Recipharm’s formulation and development teams and believe that our chemistry will fit well in their existing tool kit of solutions. We expect this agreement to help us reach new clients and to expand the use of our chemistry.”